Khiron Life Sciences closes $28.75 million bought deal financing including full exercise of
over-allotment option

28 May 2019

On May 28, 2019, Khiron Life Sciences Corp. (TSXV:KHRN) (OTCQB:KHRNF) closed its previously announced bought deal short form prospectus offering of common shares, including the exercise in full of the over-allotment option, for aggregate gross proceeds of $28,751,035. The offering was completed by a syndicate of underwriters co-led by Canaccord Genuity Corp. and BMO Capital Markets, and including AltaCorp Capital Inc. and Scotia Capital Inc.

Khiron is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. In May 2018 , Khiron listed on the TSXV, becoming the first Colombian based medical cannabis company to trade on any exchange globally.

Gowling WLG advised Khiron in this financing with a team that included Peter Simeon, Marek Lorenc, Sachin Seth and Olivia Lifman.


NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.